New Antiviral Agents for Treatment of Hepatitis CEGERMAN, ROBERT S. MD, FACOG*,†Clinical Obstetrics and Gynecology: May 13, 2019 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/GRF.0000000000000457 Original Article: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Between 70 and 170 million people worldwide are infected with hepatitis C virus (HCV) which frequently causes chronic liver disease and cirrhosis. There are several genotypes and many subtypes of HCV. Direct-acting antiviral agents are effective at eradicating HCV in the vast majority of patients, producing much higher cure rates than were seen with interferon and ribavirin regimens only a few years ago. The chapter reviews the epidemiology and virology of HCV infection. Treatment regimens are complex but a straightforward approach to selection of patients, choice of direct-acting antiviral agents and follow-up is presented. *Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine †Department of Medicine, General Internal Medicine, University of Florida College of Medicine, Gainesville, Florida The author declares that there is nothing to disclose. Correspondence: Robert S. Egerman, MD, FACOG, Box 100294, Room M-301, 1600 SW Archer Road, Gainesville, FL. E-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.